Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person17
HCW Biologics Inc.
Company
ADMA BIOLOGICS, INC.
Company
Theriva Biologics, Inc.
Company
AbCellera Biologics Inc.
Company
FibroBiologics, Inc.
Company
Bone Biologics Corp
Company
Beta Bionics, Inc.
Company
BIOLARGO, INC.
Company
BiomX Inc.
Company
20/20 Biolabs, Inc.
Company
BIOGEN INC.
Company
BIOVIE INC.
Company
BioAtla, Inc.
Company
GRI Bio, Inc.
Company
Q32 Bio Inc.
Company
BioStem Technologies, Inc.
Company
Bionano Genomics, Inc.
Company
Primary record10
HCW Biologics Inc. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. On November 3, 2026, HCW Biologics Inc. (the “Company”) entered into a Notes Purchase Agreement (the “Purchase Agreement”) with Streeterville Capital, LLC (the “Lende
HCW Biologics Inc. filed S-1
SEC form S-1 filed by HCW Biologics Inc. (CIK 1828673) on 2026-10-02.
HCW Biologics Inc. filed DEF 14A
SEC form DEF 14A filed by HCW Biologics Inc. (CIK 1828673) on 2026-10-01.
HCW Biologics Inc. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. On September 23, 2026, HCW Biologics Inc. (the Company ) entered into a Securities Purchase Agreement (the Purchase Agreement ) with an existing institutional investo
HCW Biologics Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On September 9, 2026, HCW Biologics Inc. issued Amendment No. 1 to Preliminary Proxy Statement, a copy of which is included in this Form 8-K as Exhibit 10.1. The information furnished
HCW Biologics Inc. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. On September 4, 2026, HCW Biologics Inc. (the Company ) entered into an Exclusive Distribution Agreement (the Distribution Agreement or Agreement ) with Akron Biotech
HCW Biologics Inc. filed S-1/A
SEC form S-1/A filed by HCW Biologics Inc. (CIK 1828673) on 2026-08-28.
HCW Biologics Inc. filed S-1
SEC form S-1 filed by HCW Biologics Inc. (CIK 1828673) on 2026-08-20.
HCW Biologics Inc. filed 8-K
Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. On August 10, 2026, the Audit Committee of the Board of Directors (the “Audit Committee”) of HCW Bio
HCW Biologics Inc. filed 8-K
Item 2.02 Results of Operations and Financial Condition. On August 14, 2026, HCW Biologics Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. The full text of the press rele